← All trials
NCT06981806
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Feb 28, 2027
- Completion date
- Feb 28, 2027
- First posted
- May 21, 2025
- Last posted
- Nov 19, 2025
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cedars-Sinai Medical CenterLead sponsor
- Cedars-Sinai Medical CenterOfficial
- Cedars-Sinai Medical CenterSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.